Clinical Trials
20 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT02533258 2025-07-16
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Pfizer
Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed
NCT03154190 2025-01-24
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
Phase NA Completed
NCT04436120 2024-12-03
TRANSLATE
Pfizer
Phase NA Terminated
NCT01881620 2024-11-18
COMBITEP
Institut Bergonié
Phase NA Completed
NCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01651078 2024-04-15
LAASR
Monteris Medical
Completed
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03727841 2022-07-27
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04033432 2022-04-27
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Northwestern University
Phase 2 Unknown
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00995007 2016-03-29
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01778530 2015-10-07
TRC105 for Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00908232 2015-01-15
SEQUENTIAL
Janssen-Cilag International NV
Phase 2 Completed
NCT00393094 2012-07-13
Bevacizumab and Irinotecan to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00171925 2012-04-11
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Phase 3 Terminated